SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056288
Filing Date
2024-05-09
Accepted
2024-05-09 07:45:32
Documents
72
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q glue-20240331.htm   iXBRL 10-Q 1320258
2 EX-3.3 glue-ex3_3.htm EX-3.3 208089
3 EX-31.1 glue-ex31_1.htm EX-31.1 16755
4 EX-32.1 glue-ex32_1.htm EX-32.1 9962
  Complete submission text file 0000950170-24-056288.txt   6693730

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20240331.xsd EX-101.SCH 1088300
76 EXTRACTED XBRL INSTANCE DOCUMENT glue-20240331_htm.xml XML 1023091
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 24928624
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)